Skip to content
value.today
Verrica Pharmaceuticals Inc. logo

Verrica Pharmaceuticals Inc.

VRCA
$76 Mmarket cap on Sep 21, 2026-73.3% since Jan 2024
Compare
World rank
#19,728
Revenue
$36 M
For year ending December-2025
Net income
$-18 M
-50.3% margin
SEC filing
Employees
76
As of December 31, 2025
SEC filing

Verrica Pharmaceuticals Inc. in brief

Verrica Pharmaceuticals Inc. is a listed company in the Biotechnology industry, based in West Chester, Pennsylvania, USA. It was founded in 2013. Its market value was $76 M on 21 September 2026, which makes it the 19,728th largest listed company in the world and the 3,666th largest in the USA on this site. In the year to December 2025 it had sales of $36 M and a net loss of $18 M. It employs about 76 people and Jayson Rieger is its chief executive. Its largest product and service lines by sales in 2025 were License and collaboration revenue (57%) and License and Collaboration Revenue, Commercial Supply and Development (6%). Its shares trade under the symbol VRCA (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Verrica Pharmaceuticals Inc.

We are a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Currently, our commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Our commercial product, YCANTH (VP-102), was approved by the U.S. Food and Drug Administration, or FDA, in July 2023 for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are currently developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Our second development candidate, VP-315 (ruxotemitide), is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, or BCC.

From the company's annual report filed with the US SEC: read the report

Verrica Pharmaceuticals Inc. timeline

4 events, 2013–2025
  1. 2013
  2. 🏁
    · approximate
    Founded
  3. 2015
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2018
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 15 June 2018; shares registered for exchange trading on 13 June 2018.
  7. 2025
  8. 💰
    Record revenue of $36 million
    FY2025, the highest of the 5 years on record.

Events of Verrica Pharmaceuticals Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$108 M$217 M$325 M$433 M2020202120222023202420252026

World rank over time

▼ down 7,640 places since 2020
2020-01-01: #12180#12,18020202021-01-01: #13724#13,72420212022-01-07: #17721#17,72120222022-12-25: #21504#21,50420222023-07-30: #17039#17,03920232024-01-05: #16041#16,04120242026-03-08: #10210#10,21020262026-08-01: #17886#17,88620262026-09-21: #19820#19,8202026

Rank in USA: #2,647 (Jan 2020) · #2,962 (Jan 2021) · #3,641 (Jan 2022) · #4,263 (Dec 2022) · #3,443 (Jul 2023) · #2,970 (Jan 2024) · #1,984 (Mar 2026) · #3,513 (Aug 2026) · #3,646 (Sep 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
2.5×
Price / book
3.1×
Free cash flow yield
-23.1%
Net margin (TTM)
-102.8%
Operating margin
-34.2%
Return on equity
-126.0%
Liabilities / assets
47.5%
Net debt
$-30M
Revenue growth
+370.0%
R&D / revenue
24.9%
Revenue per employee
$468 K
Profit per employee
$-235 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-21M—FY18Fiscal year ending Dec 2019: revenue —, net income $-28M—FY19Fiscal year ending Dec 2020: revenue —, net income $-43M—FY20Fiscal year ending Dec 2021: revenue $12M, net income $-35M$12MFY21Fiscal year ending Dec 2022: revenue $9M, net income $-24M$9MFY22Fiscal year ending Dec 2023: revenue $5M, net income $-67M$5MFY23Fiscal year ending Dec 2024: revenue $8M, net income $-77M$8MFY24Fiscal year ending Dec 2025: revenue $36M, net income $-18M$36MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$36M+370.0%$-12M$-18M-50.3%
Dec 2024$8M+47.9%$-66M$-77M-1011.6%
Dec 2023$5M-43.3%$-66M$-67M-1308.6%
Dec 2022$9M-24.8%$-21M$-24M-271.2%
Dec 2021$12M—$-31M$-35M-292.3%
Dec 2020——$-40M$-43M—
Dec 2019——$-30M$-28M—
Dec 2018——$-22M$-21M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-18M$0M$-18M$-1.68—
Dec 2024$-61M$0M$-61M$-14.78—
Dec 2023$-39M$0M$-39M$-1.48—
Dec 2022$-19M$0M$-19M$-0.72—
Dec 2021$-28M$1M$-28M$-1.30—
Dec 2020$-30M$1M$-32M$-1.71—
Dec 2019$-27M$1M$-28M$-1.13—
Dec 2018$-18M$1M$-19M$-1.41—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$30M
Net income, trailing 12 months
$-31M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-16M—Dec ’24Three months to Mar 2025: revenue $3M, net income $-10M$3MMar ’25Three months to Jun 2025: revenue $13M, net income $0M$13MJun ’25Three months to Sep 2025: revenue $14M, net income $-0M$14MSep ’25Three months to Dec 2025 (from the annual report): revenue $5M, net income $-8M$5MDec ’25Three months to Mar 2026: revenue $5M, net income $-10M$5MMar ’26Three months to Jun 2026: revenue $6M, net income $-13M$6MJun ’26Three months to Sep 2026: revenue $7M, net income $-12M$7MSep ’26

Latest quarter to Sep 2026: revenue $7M (-51.8% on a year earlier), net income $-12M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Verrica Pharmaceuticals Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$36 M
Operating income
$-12 M
Net income
$-18 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$47 M
Total liabilities
$22 M
Total equity
$25 M

As of December-2025

Top 39 institutional investors in Verrica Pharmaceuticals Inc.#

As of Sep 30, 2026
39 institutions held 3.9 M shares (about 22.9% of the shares outstanding) on Sep 30, 2026. The ten largest hold 21.0%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Verrica Pharmaceuticals Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Caligan Partners LP923,9100 (0.00%)5.38%$4 MNov 16, 2026
2Cannell Capital LLC693,552-90,371 (-11.53%)4.04%$3 MNov 16, 2026
3Affinity Asset Advisors, LLC688,654-18,684 (-2.64%)4.01%$3 MNov 13, 2026
4Vanguard Capital Management LLC351,910+72,600 (+25.99%)2.05%$2 MNov 13, 2026
5Boothbay Fund Management, LLC280,7340 (0.00%)1.63%$1 MNov 16, 2026
6Mariner, LLC214,030+6,800 (+3.28%)1.25%$1 MNov 12, 2026
7Armistice Capital, LLC206,472-219,832 (-51.57%)1.20%$1 MNov 16, 2026
8Geode Capital Management, LLC128,298-9,862 (-7.14%)0.75%$1 MNov 6, 2026
9BlackRock, Inc.72,098-2,246 (-3.02%)0.42%$0 MNov 13, 2026
10Vanguard Fiduciary Trust Co53,505-16,668 (-23.75%)0.31%$0 MNov 13, 2026
11Citadel Advisors LLC39,002New0.23%$0 MNov 16, 2026
12Verdad Advisers, LP35,414+12,345 (+53.51%)0.21%$0 MNov 16, 2026
13Renaissance Technologies LLC31,884+10,115 (+46.47%)0.19%$0 MNov 12, 2026
14Northern Trust Corp30,806+3,810 (+14.11%)0.18%$0 MNov 16, 2026
15State Street Corp28,9160 (0.00%)0.17%$0 MNov 12, 2026
16XTX Topco Ltd28,686+14,963 (+109.04%)0.17%$0 MNov 16, 2026
17Fifth Third Bancorp28,000+14,000 (+100.00%)0.16%$0 MNov 5, 2026
18Two Sigma Investments, LP24,268-16,557 (-40.56%)0.14%$0 MNov 16, 2026
19DAFNA Capital Management LLC23,7500 (0.00%)0.14%$0 MNov 16, 2026
20Legacy Trust16,5840 (0.00%)0.10%$0 MNov 6, 2026
21Jane Street Group, LLC16,297-7,357 (-31.10%)0.09%$0 MNov 12, 2026
22Beck Mack & Oliver LLC12,0000 (0.00%)0.07%$0 MNov 16, 2026
23Morgan Stanley6,132+2,931 (+91.57%)0.04%$0 MNov 13, 2026
24Royal Bank Of Canada2,074+1,310 (+171.47%)0.01%$0 MNov 16, 2026
25Capital Analysts, LLC1,5000 (0.00%)0.01%$0 MNov 13, 2026
Show all 39: investors 26 to 39
Institutional investors 26 to 39 in Verrica Pharmaceuticals Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26UBS Group AG1,448-4,623 (-76.15%)0.01%$0 MNov 10, 2026
27Vanguard Global Advisers, LLC8620 (0.00%)0.01%$0 MNov 13, 2026
28Tower Research Capital LLC (TRC)608-6 (-0.98%)0.00%$0 MNov 16, 2026
29Salomon & Ludwin, LLC2900 (0.00%)0.00%$0 MOct 29, 2026
30New England Capital Financial Advisors LLC2000 (0.00%)0.00%$0 MNov 3, 2026
31Fortitude Family Office, LLC1270 (0.00%)0.00%$0 MOct 14, 2026
32BNP Paribas Financial Markets101-9 (-8.18%)0.00%$0 MNov 12, 2026
33Jpmorgan Chase & Co470 (0.00%)0.00%$0 MNov 12, 2026
34Caitong International Asset Management Co., Ltd28New0.00%$0 MOct 29, 2026
35Jones Financial Companies Lllp260 (0.00%)0.00%$0 MNov 13, 2026
36Valley National Advisers Inc250 (0.00%)0.00%$0 MOct 23, 2026
37PNC Financial Services Group, Inc.20-82 (-80.39%)0.00%$0 MNov 6, 2026
38FMR LLC10New0.00%$0 MNov 10, 2026
39Barclays PLC4-60 (-93.75%)0.00%$0 MNov 6, 2026

Mutual funds holding Verrica Pharmaceuticals Inc.#

17 funds hold shares worth $3 M (about 2.6% of the company). Since their previous reports 12 added shares and 3 sold, buying $1 M net.
Mutual funds holding Verrica Pharmaceuticals Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.143,141$1 M0.83%<0.01%+171%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.135,465$1 M0.79%<0.01%−0.3%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC61,808$0 M0.36%<0.01%+119%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors33,630$0 M0.20%0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC20,514$0 M0.12%<0.01%+84%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC17,055$0 M0.10%<0.01%+80%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC10,929$0 M0.06%<0.01%+20%May 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP7,373$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC2,195$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC1,982$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP2,088$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP1,645$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP800$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Avantis Total Equity Markets ETFAmerican Century ETF Trust481$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.262$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC90$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC51$0 M<0.01%<0.01%+22%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 17 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Verrica Pharmaceuticals Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$18.2 M
12 purchases, 5 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$18.2 M
open market only
Insiders on file
21
since
$18.0 M-$695 K$0Nov 2023: bought $0 (0 trades), sold $305 K (10 trades)Nov 23Dec 2023: bought $12.5 M (9 trades), sold $0 (0 trades)DecJul 2024: bought $0 (0 trades), sold $695 K (8 trades)JulAug 2024: bought $0 (0 trades), sold $382 K (10 trades)AugNov 2024: bought $0 (4 trades), sold $0 (0 trades)NovMar 2025: bought $0 (0 trades), sold $3 K (1 trades)MarNov 2025: bought $18.0 M (6 trades), sold $0 (0 trades)NovAug 2026: bought $211 K (6 trades), sold $0 (0 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
Verrica Pharmaceuticals Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed John J. KirbyInterim CFOBuy+5,000$4.930$25 K23,962Form 4
filed Noah L. RosenbergCMOBuy+2,030$4.920$10 K8,587Form 4
filed Noah L. RosenbergCMOBuy+4,200$4.910$21 K6,557Form 4
filed David ZawitzChief Operating OfficerBuy+6,000$4.980$30 K27,000Form 4
filed Jayson RiegerCEO and President, DirectorBuy+5,000$4.910$25 K207,593Form 4
filed Jayson RiegerCEO and President, DirectorBuy+20,000$5.060$101 K202,593Form 4
filed John J. KirbyInterim CFOGrant or award+10,000——18,962Form 4
filed John J. KirbyInterim CFOBuy+3,536$4.240$15 K8,962Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Verrica Pharmaceuticals Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
244,405
1.4% of shares · 4.58 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-10 reverse split ; 1.714-for-1 split

Trading halts

  • 2025-07-24 23:50 UTC, code T3, resumed 13:00 UTC

Fails to deliver

  • : 4 shares at $4.45
  • : 533 shares at $4.65
  • : 175 shares at $4.91
  • : 46 shares at $5.26
  • : 2,156 shares at $5.39

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Verrica Pharmaceuticals Inc. scorecard#

Passes 10 of the 21 checks that could be worked out: strongest in growth (4 of 5), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Sep 21, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median3.1×Price to book 3.1× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median2.5×Price to sales 2.5× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-23.1%Free cash flow is -23.1% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth4 of 5
    • ✓Revenue grew in the newest year370.0%Revenue up 370.0% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years58.0%58.0% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median58.0%58.0% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-1.68 vs -14.78Diluted EPS -1.68 in fiscal 2025 against -14.78 the year before (report's currency).
    • ✓Net income higher than five years earlier-$18 M-$18 M in fiscal 2025 against -$43 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability2 of 5
    • ✗Profitable in the newest year-$18 MNet income -$18 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median-34.2%-34.2% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-240.5%-240.5% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-34.2%-34.2% in fiscal 2025 against -235.9% in 2022.
  • Financial health3 of 5
    • ✓Short-term assets cover short-term liabilities2.6×Current ratio 2.59 at the end of fiscal 2025.
    • ✓Debt below equity0.0×Debt to equity 0.00 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $30 M at the end of fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-7.04Z-score -7.04 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year105.6%Diluted shares up 105.6% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Verrica Pharmaceuticals Inc.'s statements, beside the median of Biotechnology.

Verrica Pharmaceuticals Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-34.2%-60.5%
Net margin-50.3%-68.9%
Return on equity-240.5%-61.0%
Revenue growth, 3 years a year58.0%12.9%
Revenue growth370.0%15.8%
Debt to equity0.00×0.26×

5of 8on the Piotroski tests of financial strength

  • Net loss of $18 million, the 9th loss-making year in a row.
  • Free cash flow was negative: -$18 million.
  • The share count rose 105.6% in the year.
  • More cash than debt: net cash of $30 million.

Verrica Pharmaceuticals Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Verrica Pharmaceuticals Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017
Income statement
Revenue367.65.19.012————
Cost of revenue—2.60.5——————
Research and development8.9122012161615133.7
Selling, general and administrative35594717—————
General and administrative———172725159.10.7
Operating expenses48737130434030224.5
Operating income−12−66−66−21−31−40−30−22−4.5
Interest and finance income0.91.42.70.50.10.51.91.2—
Interest expense and finance costs7.79.44.02.24.33.0r———
Other non-operating income (expense)−5.7−11−1.2−3.2−4.2−2.51.91.2−0.0
Income tax0000—————
Net income including minority interests—−77−67−24−35−43−28−21—
Net income attributable to shareholders−18−77−67−24−35−43−28−21−4.5
Earnings per share, basic-1.68-14.78r-1.48-0.72-1.30-1.71-1.13-1.41-1.56
Earnings per share, diluted-1.68-14.78r-1.48-0.72-1.30-1.71-1.13-1.41-1.56
Shares, weighted average (basic)115.2r453427————
Shares, weighted average (diluted)115.2r4534272525152.9
Balance sheet
Cash and cash equivalents3046703416119.2108.7
Short-term investments———00————
Receivables5.30.04.20—————
Inventory2.22.51.00—————
Other current assets2.82.32.54.44.02.23.01.30.4
Current assets43517839746865919.1
Property, plant and equipment0.20.61.13.93.93.12.10.3—
Right-of-use (leased) assets0.50.81.21.41.61.80.1——
Total assets47548245807468929.1
Accounts payable2.11.92.50.50.80.31.20.90.2
Debt due within a year0130——35———
Current liabilities1629173.546393.42.50.6
Lease liabilities (non-current)0.20.60.91.21.41.70.1——
Total liabilities2264624.748413.42.50.6
Retained earnings−325−307−230−163−139−104−61−33−12
Shareholders' equity25−9.9204033336589−7.0
Total liabilities and equity47548245807468929.1
Shares outstanding179.2r4241282526263.7
Cash-flow statement
Share-based compensation3.37.2145.06.19.83.32.30.1
Cash from operating activities−18−61−39−19−28−30−27−18−4.6
Capital expenditure0−0.0−0.4−0.3−0.9−1.5−0.7−0.8r—
Cash from investing activities0−0.0−0.454−1.0−3.626−80—
Shares issued———2728————
Cash from financing activities1.43874−1734350.49913
Change in cash−16−2335195.11.4−1.01.68.1
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Verrica Pharmaceuticals Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • License and collaboration revenue$20 M57%
  • Product revenue, net(total)$15 M43%
  • License and Collaboration Revenue, Commercial Supply and Development$2 M6.5%

Business segments

  • Operating$36 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Verrica Pharmaceuticals Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$741 K
Jayson Rieger
Other top executives, average
$906 K
the CEO earned 0.8× this
$100 invested is now
$30
Verrica Pharmaceuticals Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Jayson Rieger$741 K$437 K$906 K$30
2024Ted White, Jayson Rieger$2.6 M−$468 K$1.2 M$25
2023Ted White$3.5 M$4.6 M$2.3 M$266

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Verrica Pharmaceuticals Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 3 · Restructuring 1 · Directors and officers 10 · Material agreement 5 · Unregistered share sale 1 · Shareholder rights changed 1 · Shareholder vote 2 · Results announced 9

Verrica Pharmaceuticals Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Results announced8-K
Delisting notice8-K
Shareholder rights changed8-K
Material agreement8-K
Material agreement8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Delisting notice8-K
Directors and officers8-K
Material agreement8-K
Directors and officersResults announced8-K
Delisting noticeDirectors and officers8-K
Restructuring8-K
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of Verrica Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2025$50 MPrivate placement after listing$50 to $250 million21equity, optionsSEC
Feb 2018$20 MNo. 3$10 to $50 million2equitySEC
Dec 2017$5 MNo. 2$2 to $10 million1equitySEC
Dec 2015$2 MNo. 1$2 to $10 million14equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

FDA drug approvals: Verrica Pharmaceuticals Inc.#

1 approved applications held; 1 approvals and 0 new uses in 2023.

Approvals held
1
New molecular entities
0
New uses approved
0
efficacy supplements
Generics
0
1 new drugs, 0 biologics
Verrica Pharmaceuticals Inc.: latest FDA approvals
ApprovedDrugKind
2023-07-21YcanthCantharidin · NDA212905New drug (NDA)

Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (VERRICA PHARMS), so they follow acquisitions

Layoffs at Verrica Pharmaceuticals Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
67
2022–2024
Latest
47 people
2024-10-01
Verrica Pharmaceuticals Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2024·········47··47
2022····20·······20
Verrica Pharmaceuticals Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
47 peopleRestructuring planSEC 8-K“(the “Company”) announced a reduction of its workforce by 47 employees, which the Company expects to be substantially completed by October 1, 2024.”Filing
20 peopleRestructuring planSEC 8-K“(the “Company”), in order to streamline operations and reduce costs, approved a plan to reduce its workforce by terminating 20 employees, which the Company expects to be completed …”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Verrica Pharmaceuticals Inc. compares in Biotechnology

  • Market cap$76 M · higher than 32% of 726
  • Revenue$36 M · higher than 56% of 647
  • Net margin-102.8% · higher than 41% of 408
  • Revenue growth370.0% · higher than 93% of 438
  • Price / sales2.5× · lower than 81% of 339
  • Price / book3.1× · lower than 48% of 534
  • FCF yield-23.1% · higher than 41% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Verrica Pharmaceuticals Inc.🇺🇸$76 M—-102.8%+370.0%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Sep 21, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Verrica Pharmaceuticals Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Verrica Pharmaceuticals Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Verrica Pharmaceuticals Inc.? Suggest a correction